ImmunoScape Pte. Ltd., an A*STAR spin out backed by Amgen Ventures and EDBi that is developing next-generation TCR-based cancer immunotherapies, today announced an exclusive in-licensing deal with Cue ...
RPT1G is the first well-tolerated NAMPT inhibitor, demonstrating safety in healthy volunteers at single and multiple ascending dose levels.Target ...
Cancer treatment has come a long way, but many of today's therapies still come with steep costs: not just financial, but ...
New data show that dual-target CAR T therapy induces durable remissions in children with high-risk B-cell leukaemia, offering ...
March Biosciences (March Bio), a clinical stage biotechnology company developing cell therapies for hard-to-treat cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted ...
Researchers succeeded in creating cells whose proliferation can be controlled. The technique enables new and safe cell therapies. Cell therapies could help in the treatment of hereditary diseases, ...
Q3 2025 Earnings Call Transcript November 14, 2025 MiNK Therapeutics, Inc. beats earnings expectations. Reported EPS is ...
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to tinostamustine, an investigational therapeutic from Purdue Pharma L.P., for the treatment of patients with malignant ...
A large Danish study found that an insufficient endometrial biopsy may slightly increase endometrial cancer risk. Learn more about the findings.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback